{"gene":"CSF3","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2005,"finding":"G-CSF acts directly on cardiomyocytes by binding the G-CSF receptor expressed on their surface, activating the JAK/STAT3 pathway, inducing antiapoptotic proteins, inhibiting cardiomyocyte apoptosis, and reducing endothelial cell apoptosis; all these effects were abolished by overexpression of a dominant-negative STAT3 mutant in cardiomyocytes.","method":"Dominant-negative STAT3 transgenic overexpression in cardiomyocytes; in vivo myocardial infarction model; immunostaining and apoptosis assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative genetic rescue experiment with defined molecular pathway, rigorous loss-of-function controls, replicated across multiple outcome measures in vivo","pmids":["15723072"],"is_preprint":false},{"year":2005,"finding":"G-CSF down-regulates CXCR4 expression on bone marrow Gr1+ myeloid cells in a cell-autonomous manner (G-CSF receptor is expressed on these cells), thereby attenuating SDF-1/CXCR4-mediated retention and promoting myeloid cell mobilization from bone marrow to peripheral blood.","method":"Flow cytometry of purified Gr1+ bone marrow cells treated with G-CSF in vitro; migration and attachment assays with SDF-1; in vivo G-CSF mobilization in mice","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional assays on purified cells plus corroborating in vivo model, two orthogonal methods (surface CXCR4 measurement + migration assay)","pmids":["16537807"],"is_preprint":false},{"year":2005,"finding":"G-CSF treatment potently inhibits osteoblast activity (measured by histomorphometry and osteocalcin expression) and decreases CXCL12 mRNA and protein in bone marrow through an indirect mechanism, since the G-CSF receptor is not expressed on osteoblasts; reduced CXCL12/CXCR4 signaling leads to hematopoietic progenitor cell mobilization.","method":"Transgenic mice with targeted G-CSF receptor mutations; histomorphometry; CXCL12 mRNA and protein measurement; cell sorting to identify CXCL12-producing cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple receptor mutant mouse lines with graded mobilization phenotypes correlated to CXCL12 levels, cell-type-specific receptor absence confirmed, multiple orthogonal methods","pmids":["16037394"],"is_preprint":false},{"year":2004,"finding":"Truncated G-CSF receptor mutants (found in SCN/AML) lose the SOCS3 recruitment site Tyr729 and show defective receptor internalization, resulting in reduced SOCS3 expression and loss of SOCS3-mediated STAT5 inhibition while STAT3 inhibition remains intact, leading to an increased STAT5/STAT3 activation ratio and hyperproliferative responses to G-CSF.","method":"Luciferase reporter assays for STAT3/STAT5 activation; SOCS3 expression measurement in bone marrow of gcsfr-d715 mice; receptor internalization assays; site-directed mutagenesis of Tyr729","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis identifying specific tyrosine residue, reporter assays, corroborated in mouse model, multiple orthogonal methods","pmids":["15069015"],"is_preprint":false},{"year":2005,"finding":"STAT3 functions as a negative regulator of G-CSF signaling by inducing SOCS3 expression; in Stat3-deficient hematopoietic cells, SOCS3 expression is nearly absent, ERK1/2 activation is enhanced and sustained, and the augmented G-CSF-induced proliferation is abrogated by MEK1 inhibition, identifying ERK as the major driver of proliferation downstream of G-CSF when STAT3 is absent.","method":"Conditional Stat3-knockout mice in hematopoietic cells; MEK1 inhibitor treatment; Western blotting for ERK and SOCS3; bone marrow colony assays","journal":"Stem cells (Dayton, Ohio)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function mouse model plus pharmacological rescue, multiple downstream readouts, clear epistasis established","pmids":["15671148"],"is_preprint":false},{"year":2006,"finding":"G-CSF induces expression of E-selectin ligands HCELL and an ~65 kDa ligand on myeloid cells by upregulating glycosyltransferases (ST3GalIV, FucT-IV, FucT-VII), leading to heightened myeloid cell adhesion to inflamed endothelium under physiologic flow conditions.","method":"Parallel plate flow assay; intravital microscopy; enzymatic treatments; biochemical characterization of E-selectin ligands; RT-PCR for glycosyltransferases; in vitro G-CSF treatment of normal human bone marrow cells","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (flow assay, intravital microscopy, enzymatic ablation, gene expression), direct mechanistic link from glycosyltransferase induction to functional adhesion","pmids":["16980970"],"is_preprint":false},{"year":2010,"finding":"G-CSF promotes Th17 differentiation (amplifying IL-17 production in CD4 and CD8 T cells) through a mechanism dependent on and downstream of G-CSF-induced IL-21 signaling; donor IL-17A controls macrophage infiltration into skin and cutaneous fibrosis after transplantation.","method":"Murine hematopoietic transplantation model; cytokine blocking/knockout mice (IL-17A, IL-21); intracellular cytokine staining; flow cytometry","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (IL-21 and IL-17A knockout) placing G-CSF upstream of IL-21 and IL-17 in a defined pathway, replicated with multiple cytokine interventions","pmids":["20435882"],"is_preprint":false},{"year":2010,"finding":"G-CSF transcription factor Gfi1 regulates G-CSF-induced Erk1/2 activation and granulocytic differentiation through transcriptional control of the Ras activator RasGRP1; Gfi1-null myeloid cells selectively fail to activate Erk1/2 (but not STAT1/3) in response to G-CSF, and forced RasGRP1 expression rescues this defect.","method":"Gfi1-knockout mice; retroviral RasGRP1 transduction rescue experiment; Western blotting for Erk1/2, STAT1, STAT3 activation; colony assays; RT-PCR","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with selective signaling defect identified, epistasis confirmed by rescue experiment, two orthogonal methods","pmids":["20203268"],"is_preprint":false},{"year":2011,"finding":"G-CSF activates Lyn (the predominant Src kinase in myeloid cells) through Gab2-mediated recruitment of the Shp2 phosphatase, which dephosphorylates inhibitory phospho-Tyr507 on Lyn; Gab2 Tyr507 dephosphorylation was abrogated in Shp2-deficient cells and by Gab2 mutations preventing Shp2 binding.","method":"Co-immunoprecipitation; in vitro kinase/phosphatase assays with purified proteins; Shp2-deficient cells; Gab2 mutants; siRNA knockdown of Gab2","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro reconstitution of phosphatase activity on specific tyrosine residue plus mutagenesis and genetic KO, multiple orthogonal methods","pmids":["21636860"],"is_preprint":false},{"year":2008,"finding":"G-CSF stimulates Jak2-dependent phosphorylation of Gab2 at Tyr643, which recruits Shp2 and leads to Erk1/2 activation and cell proliferation; mutation of Gab2 Tyr643 inhibited G-CSF-stimulated Erk1/2 activation, Shp2 binding, and Gab2-mediated proliferation.","method":"JAK inhibitor treatment; Jak2 antisense and dominant-negative constructs; in vitro kinase assay with activated Jak2; Gab2 site-directed mutagenesis; cell proliferation assays","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro reconstitution with Jak2 phosphorylating Gab2, site-directed mutagenesis confirming key residue, multiple orthogonal approaches","pmids":["18644434"],"is_preprint":false},{"year":2001,"finding":"G-CSF receptor signals cooperate with C/EBPα to induce myeloperoxidase (MPO) and neutrophil elastase (NE) gene expression; receptor tyrosine mutations revealed that all four cytoplasmic tyrosines are required for NE induction, while mutation of Tyr704 specifically enhanced MPO induction, indicating distinct tyrosine requirements for different myeloid differentiation genes.","method":"Ba/F3 cells co-expressing C/EBPα-ER and G-CSF receptor mutants; RT-PCR for MPO, NE, LF, PU.1; tyrosine-to-alanine mutant receptors","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — systematic site-directed mutagenesis of receptor tyrosines with gene expression readouts, reconstitution in defined cell line","pmids":["11368439"],"is_preprint":false},{"year":2006,"finding":"The G-CSF receptor requires the membrane-proximal box 1 PDP (PXP) motif for activation of Jak1, Jak2, and Tyk2, tyrosine phosphorylation of the receptor, and STAT3/STAT1 recruitment; Jak kinases are not activated in terminally differentiated neutrophils upon G-CSF stimulation, indicating utilization of alternative signaling pathways in mature cells.","method":"G-CSF receptor Pro639Ala/Pro641Ala mutant transfected into Ba/F3 and NFS-60 cells; kinase immunoprecipitation and phosphorylation assays; comparison between proliferating cell lines and primary neutrophils","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — site-directed mutagenesis identifying required motif, compared in proliferating vs. terminally differentiated primary cells, multiple kinases assessed","pmids":["9015216"],"is_preprint":false},{"year":2006,"finding":"The G-CSF receptor complex has 2:2 stoichiometry with two binding sites on both ligand and receptor equivalent to site II and site III of the IL-6 receptor complex; structure of the ligand-binding domain was determined by crystallography in complex with G-CSF.","method":"Crystal structure of partial ligand-receptor complex; mutagenesis of receptor and ligand; neutralizing antibody mapping; solution-phase binding studies","journal":"Frontiers in bioscience : a journal and virtual library","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — crystal structure plus mutagenesis reported, but this is a review compiling multiple prior studies, not a single primary paper; confidence moderate given secondary synthesis","pmids":["16720384"],"is_preprint":false},{"year":2008,"finding":"Serum amyloid A (SAA) induces G-CSF gene expression in macrophages via Toll-like receptor 2 (TLR2); SAA stimulation activates NF-κB and promotes binding to the CK-1 element of the G-CSF promoter; this effect is blocked by anti-TLR2 antibody and absent in TLR2-deficient macrophages.","method":"TLR2-knockout macrophages; anti-TLR2 antibody blockade; NF-κB activation assay; chromatin immunoprecipitation (promoter binding); in vitro reconstitution; in vivo SAA injection in wild-type vs. G-CSF- or TLR2-deficient mice","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO macrophages, antibody blockade, ChIP assay, and in vivo rescue, multiple orthogonal methods confirming TLR2→NF-κB→G-CSF promoter pathway","pmids":["18952897"],"is_preprint":false},{"year":2015,"finding":"G-CSF selectively activates STAT3 within neuroblastoma cancer stem cell (CSC) subpopulations via G-CSF receptor; STAT3 acts in a feed-forward loop to transcriptionally activate G-CSF receptor expression; blockade with anti-G-CSF antibody or STAT3 inhibitor depleted CSC subpopulation, inhibited tumor growth, decreased metastasis, and increased chemosensitivity.","method":"In vitro CSC expansion assays; human xenograft and murine neuroblastoma tumor models; anti-G-CSF antibody blockade; STAT3 inhibitor; reporter assays for G-CSFR transcription","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — two in vivo tumor models plus in vitro mechanistic dissection with pharmacological blockade and antibody neutralization, feed-forward loop confirmed by transcriptional reporter","pmids":["25908586"],"is_preprint":false},{"year":2011,"finding":"G-CSF receptor (G-CSFR) is expressed on myoblasts during embryonic development and transiently on regenerating myocytes in injured adult skeletal muscle; neutralization of endogenous G-CSF impairs muscle regeneration, exogenous G-CSF promotes myoblast proliferation, and muscle regeneration is markedly impaired in G-CSFR-knockout mice.","method":"G-CSFR-knockout mice; G-CSF neutralizing antibody; BrdU proliferation assay; in vivo muscle injury model; immunostaining","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor KO, antibody neutralization, and exogenous cytokine rescue with defined proliferative readout; multiple orthogonal approaches","pmids":["21422169"],"is_preprint":false},{"year":2015,"finding":"G-CSF receptor is asymmetrically expressed in activated satellite cells; G-CSF positively affects the satellite cell population during multiple differentiation stages; G-CSF supports long-term muscle regeneration, functional maintenance, and lifespan extension in mdx mouse models of Duchenne muscular dystrophy.","method":"Ex vivo fiber culture assay; immunostaining for asymmetric G-CSFR expression; in vivo G-CSF treatment of mdx and more severe DMD mouse models; functional assessments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization of receptor to satellite cells with functional consequence, multiple DMD models, ex vivo and in vivo corroboration","pmids":["25865621"],"is_preprint":false},{"year":2006,"finding":"G-CSF protects dopaminergic neurons from 6-OHDA toxicity via the ERK pathway (not JAK/STAT); G-CSF activates ERK, increases phosphorylation of Bad, restores Bcl-xL levels, and inhibits caspase-3 activation; ERK inhibition abrogates all these protective effects.","method":"Primary mesencephalic cultures; 6-OHDA neurotoxicity model; Western blotting for ERK, p-Bad, Bcl-xL, caspase-3; MEK/ERK inhibitor pharmacological blockade; immunostaining","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple downstream readouts, single lab, no genetic KO confirmation","pmids":["16839644"],"is_preprint":false},{"year":2014,"finding":"G-CSF attenuates neuronal apoptosis after neonatal hypoxia-ischemia via PI3K/Akt-dependent inhibition of GSK-3β activity, reducing caspase-3 activation and increasing Bcl-2/Bax ratio; this neuroprotective effect is abolished by G-CSF receptor siRNA or PI3K inhibitor Wortmannin.","method":"Neonatal rat HI model; G-CSFR siRNA; GSK-3β siRNA; PI3K inhibitor Wortmannin; Western blotting; TUNEL assay; immunofluorescence","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-level KD confirming requirement for G-CSFR, PI3K inhibitor placing Akt upstream of GSK-3β, single lab","pmids":["25448005"],"is_preprint":false},{"year":2015,"finding":"G-CSF activates autophagy in both neutrophils and hematopoietic stem cells (HSCs); G-CSF-induced neutrophil and HSC mobilization is impaired in the absence of autophagy, whereas direct HSC mobilization by the CXCR4 antagonist AMD3100 does not require autophagy, placing autophagy as a specific requirement downstream of G-CSF signaling for mobilization.","method":"Autophagy-deficient mouse models; G-CSF vs. AMD3100 mobilization comparison; flow cytometry; autophagy flux assays in murine and human donor cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic autophagy KO demonstrating G-CSF-specific requirement, negative control with AMD3100 establishing specificity, replicated in mouse and human","pmids":["25788702"],"is_preprint":false},{"year":2015,"finding":"G-CSF activates PLCγ2, PKC, JAK-1, and STAT-3 in myeloid progenitors during granulocytic commitment; STAT-3 activation and increased PU.1 expression downstream of G-CSF are sensitive to PLC inhibition, placing PLCγ2 upstream of JAK/STAT and PU.1 in G-CSF-induced granulopoiesis.","method":"Flow cytometry; RNA interference (PLCγ2 shRNA); PLCγ/PKC inhibitors; Western blotting for JAK1, STAT3, PU.1; colony-forming unit assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown plus pharmacological inhibition establishing pathway hierarchy, single lab, no structural validation","pmids":["24038146"],"is_preprint":false},{"year":2015,"finding":"LPS-induced G-CSF expression in macrophages is mediated specifically by ERK2 (not ERK1); ERK2 and C/EBPβ synergistically activate the G-CSF promoter; ERK2 promotes LPS-induced binding of NF-κB (p50/p65) and C/EBPβ to the G-CSF promoter through chromatin remodeling.","method":"shRNA knockdown of ERK1 vs. ERK2; G-CSF promoter-luciferase reporter assays; chromatin immunoprecipitation (ChIP); DNase I accessibility assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — isoform-specific shRNA plus ChIP and reporter assay plus chromatin remodeling assay, mechanistic pathway from ERK2 to G-CSF transcription fully demonstrated","pmids":["26114754"],"is_preprint":false},{"year":2019,"finding":"Tissue injury induces emergency hematopoiesis through an IL-1/MyD88-dependent pathway that drives G-CSF production; G-CSF then expands hematopoietic progenitors including HSCs and MPPs and increases myeloid-skewed progenitor frequency.","method":"Mouse polytrauma model; IL-1 receptor/MyD88-knockout mice; ELISA for G-CSF; flow cytometry of bone marrow progenitors","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO establishing IL-1/MyD88 pathway upstream of G-CSF, single lab, limited mechanistic depth beyond cytokine production","pmids":["30988118"],"is_preprint":false},{"year":2011,"finding":"G-CSF improves neutrophil function in G6PC3-deficient mice by modulating apoptotic mediators (normalizing p-Akt, PI3K, and active caspase-3 levels) and rectifying energy homeostasis (increasing glucose uptake and intracellular G6P, lactate, and ATP levels) in vivo.","method":"G6pc3-knockout mice; in vivo G-CSF therapy; Western blotting for p-Akt, caspase-3; glucose uptake assay; metabolite measurement; in vitro apoptosis assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with multiple in vivo biochemical readouts, single lab","pmids":["21292774"],"is_preprint":false},{"year":2023,"finding":"G-CSF is the key driver of autoinflammation in APLAID (PLCG2 gain-of-function missense mutation model); treatment with an anti-G-CSF antibody completely reversed established disease in APLAID mice, normalized myelopoiesis, and restored lymphocyte counts; bone marrow transplantation from healthy donors reduced G-CSF production (predominantly from non-hematopoietic cells) and fully rescued APLAID mice.","method":"APLAID knock-in mouse model; anti-G-CSF antibody treatment; bone marrow transplantation; cytokine profiling; flow cytometry of immune cell populations","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic disease model with antibody rescue plus bone marrow transplantation epistasis identifying non-hematopoietic source of G-CSF, multiple orthogonal interventions","pmids":["36997670"],"is_preprint":false},{"year":2018,"finding":"IFNγ suppresses G-CSF signaling by increasing SOCS3 expression in neutrophils, leading to neutrophil apoptosis; depletion of G-CSF (but not GM-CSF) in IFNγ-deficient mice induces neutrophil apoptosis and restores IL-10 secretion, identifying IFNγ-SOCS3 as a negative regulator of G-CSF-driven neutrophil expansion.","method":"IFNγ-knockout mice; G-CSF or GM-CSF depletion antibodies; SOCS3 expression measurement; neutrophil apoptosis assays; cytokine profiling","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus antibody depletion establishing epistasis, cytokine specificity confirmed by GM-CSF negative control, single lab","pmids":["29352287"],"is_preprint":false},{"year":2013,"finding":"CSF3R (G-CSF receptor) undergoes lysine ubiquitination and redox-controlled phosphatase-modulated signaling during endocytosis; receptor routing through signaling endosomes—where interactions with the endoplasmic reticulum occur—is a key mechanism for modulating CSF3R signal amplitude and duration leading first to myeloid progenitor proliferation and then to differentiation.","method":"Review summarizing biochemical and cell biology studies on CSF3R ubiquitination, endosomal trafficking, and phosphatase activities","journal":"Frontiers in bioscience (Landmark edition)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review article summarizing prior findings; no single new primary experiment described in the abstract","pmids":["23276911"],"is_preprint":false},{"year":2020,"finding":"Cancer-associated adipocyte-derived G-CSF promotes breast cancer cell migration and invasion by activating STAT3 signaling; downstream targets include MMP2 and MMP9; G-CSF-neutralizing antibody, STAT3 inhibitor, or Stat3 siRNA each abrogate CAA- or G-CSF-induced cancer cell migration and invasion.","method":"Primary cancer-associated adipocyte isolation; recombinant G-CSF treatment; G-CSF-neutralizing antibody; Stat3 siRNA; Western blotting; migration/invasion assays; transcriptome sequencing","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization, RNAi, and small-molecule inhibition converging on STAT3→MMP2/9 axis, single lab","pmids":["32242230"],"is_preprint":false},{"year":2019,"finding":"G-CSF partially mediates bone loss induced by Staphylococcus aureus infection by suppressing osteoblast function; G-CSF levels are elevated in infected bone marrow (partly due to increased F4/80+ macrophages), and G-CSF neutralizing antibody treatment significantly rescues bone volume and preserves osteocalcin- and osterix-positive osteoblasts.","method":"Mouse S. aureus infection model; ELISA for G-CSF in bone marrow and serum; G-CSF neutralizing antibody; microCT; immunohistochemistry","journal":"Clinical science (London, England : 1979)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization with defined bone histological readout, macrophage source identified, single lab","pmids":["31175224"],"is_preprint":false}],"current_model":"CSF3 (G-CSF) binds its homodimeric receptor (G-CSFR/CSF3R) expressed on myeloid progenitors, mature neutrophils, and various non-hematopoietic cells, activating membrane-proximal JAK1/JAK2 via a conserved Box1 PXP motif, which phosphorylates STAT3, STAT5, Gab2 (at Tyr643), and the Src kinase Lyn (via Gab2-recruited Shp2 dephosphorylating inhibitory Tyr507), leading to downstream ERK1/2 and PI3K/Akt activation; STAT3 provides negative feedback by inducing SOCS3 (which suppresses further STAT5 and receptor signaling), while truncating receptor mutations lose this control to yield hyperactive STAT5 signaling associated with leukemic transformation; G-CSF also indirectly mobilizes hematopoietic stem and progenitor cells by suppressing osteoblast-derived CXCL12 and directly downregulating CXCR4 on myeloid cells through an autophagy-dependent mechanism; beyond hematopoiesis, G-CSF acts on cardiomyocytes, myoblasts, and neurons via the same receptor to activate JAK/STAT3, ERK, and PI3K/Akt survival pathways, promotes Th17 differentiation via IL-21 in T cells, and induces E-selectin ligand expression on myeloid cells through glycosyltransferase upregulation."},"narrative":{"mechanistic_narrative":"CSF3 (G-CSF) is a secreted cytokine that signals through the G-CSF receptor (CSF3R) to drive granulopoiesis, myeloid cell mobilization and inflammation, while also exerting receptor-dependent survival effects on diverse non-hematopoietic tissues [PMID:16037394, PMID:21422169]. Receptor engagement is initiated through the membrane-proximal box1 PXP motif, which is required to activate Jak1, Jak2 and Tyk2 and to recruit STAT3/STAT1 to the phosphorylated receptor [PMID:9015216], with the ligand-receptor complex assembling in a 2:2 stoichiometry [PMID:16720384]. Downstream of the Jaks, G-CSF stimulates Jak2-dependent phosphorylation of Gab2 at Tyr643, recruiting the phosphatase Shp2 to drive Erk1/2 activation and proliferation [PMID:18644434], and the same Gab2–Shp2 module activates the Src kinase Lyn by dephosphorylating its inhibitory Tyr507 [PMID:21636860]; granulocytic Erk1/2 output additionally depends on Gfi1-driven transcription of the Ras activator RasGRP1 [PMID:20203268] and on PLCγ2 acting upstream of JAK/STAT3 and PU.1 [PMID:24038146], with C/EBPα cooperating with discrete receptor tyrosines to induce myeloperoxidase and neutrophil elastase [PMID:11368439]. STAT3 imposes negative feedback by inducing SOCS3, restraining ERK and STAT5 output, and truncating SCN/AML receptor mutants that lose the Tyr729 SOCS3 site escape this control to yield a hyperproliferative high-STAT5 state [PMID:15069015, PMID:15671148]. In hematopoiesis G-CSF mobilizes stem/progenitor and myeloid cells both indirectly, by suppressing osteoblast-derived CXCL12 [PMID:16037394], and cell-autonomously, by downregulating CXCR4 on Gr1+ cells [PMID:16537807], with mobilization requiring autophagy [PMID:25788702], and it enhances myeloid adhesion by inducing E-selectin ligands through glycosyltransferase upregulation [PMID:16980970]. CSF3 transcription is itself driven by inflammatory inputs including SAA via TLR2/NF-κB [PMID:18952897], LPS via ERK2/C/EBPβ/NF-κB chromatin remodeling [PMID:26114754], and IL-1/MyD88 during emergency hematopoiesis [PMID:30988118]. Beyond blood, G-CSF activates JAK/STAT3 anti-apoptotic signaling in cardiomyocytes [PMID:15723072], supports myoblast and satellite-cell-dependent muscle regeneration via CSF3R [PMID:21422169, PMID:25865621], and protects neurons through ERK and PI3K/Akt–GSK-3β survival pathways [PMID:16839644, PMID:25448005]. G-CSF is a pathogenic driver in the PLCG2 gain-of-function autoinflammatory disease APLAID, where anti-G-CSF antibody fully reverses disease, and it promotes tumor stem-cell maintenance and cancer cell invasion through STAT3 [PMID:36997670, PMID:25908586, PMID:32242230].","teleology":[{"year":2001,"claim":"Established that distinct cytoplasmic tyrosines of the G-CSF receptor specify induction of different myeloid differentiation genes in cooperation with C/EBPα, resolving how a single receptor encodes program-specific outputs.","evidence":"Ba/F3 cells co-expressing C/EBPα-ER with tyrosine-to-alanine G-CSFR mutants, RT-PCR for MPO/NE/PU.1","pmids":["11368439"],"confidence":"High","gaps":["Cofactor mechanism linking each tyrosine to a specific gene not defined","Reconstitution in non-Ba/F3 primary progenitors not shown"]},{"year":2004,"claim":"Defined how leukemia-associated receptor truncations subvert signaling by removing the Tyr729 SOCS3 site, decoupling STAT5 inhibition from intact STAT3 inhibition to produce a hyperproliferative state.","evidence":"STAT3/STAT5 luciferase reporters, SOCS3 measurement in gcsfr-d715 mice, internalization assays, Tyr729 mutagenesis","pmids":["15069015"],"confidence":"High","gaps":["Direct link to leukemic transformation in patients not established","Mechanism connecting internalization defect to SOCS3 loss not fully resolved"]},{"year":2005,"claim":"Showed STAT3 acts as a negative regulator of G-CSF signaling via SOCS3, with ERK becoming the dominant proliferative driver when STAT3 is absent, defining the feedback architecture of the pathway.","evidence":"Conditional Stat3-knockout hematopoietic cells, MEK1 inhibitor, ERK/SOCS3 Western blots, colony assays","pmids":["15671148"],"confidence":"High","gaps":["Quantitative balance between STAT3, STAT5 and ERK in normal granulopoiesis not mapped"]},{"year":2005,"claim":"Demonstrated that G-CSF mobilizes hematopoietic cells through two routes—indirect suppression of osteoblast-derived CXCL12 and cell-autonomous CXCR4 downregulation on myeloid cells.","evidence":"G-CSFR mutant transgenic mice, histomorphometry and CXCL12 measurement; flow cytometry and SDF-1 migration assays on Gr1+ cells","pmids":["16037394","16537807"],"confidence":"High","gaps":["Indirect signal from G-CSFR-bearing cells to osteoblasts not identified","Relative contribution of each route to net mobilization unquantified"]},{"year":2005,"claim":"Extended G-CSF function beyond hematopoiesis by showing direct receptor-mediated JAK/STAT3 anti-apoptotic protection of cardiomyocytes.","evidence":"Dominant-negative STAT3 transgenic cardiomyocytes in an in vivo myocardial infarction model","pmids":["15723072"],"confidence":"High","gaps":["Upstream Jak isoform usage in cardiomyocytes not specified","Translation to human cardiac repair untested in this work"]},{"year":2006,"claim":"Identified the membrane-proximal box1 PXP motif as essential for Jak1/Jak2/Tyk2 activation and STAT recruitment, and revealed that mature neutrophils use Jak-independent alternative pathways.","evidence":"Pro639Ala/Pro641Ala G-CSFR mutants in Ba/F3 and NFS-60 cells; kinase assays compared with primary neutrophils","pmids":["9015216"],"confidence":"High","gaps":["Identity of the alternative Jak-independent pathway in neutrophils not defined"]},{"year":2006,"claim":"Resolved the architecture of ligand-receptor engagement, establishing a 2:2 stoichiometry analogous to IL-6 receptor site II/site III interactions.","evidence":"Crystal structure of ligand-binding domain with G-CSF plus mutagenesis and antibody mapping (review synthesis)","pmids":["16720384"],"confidence":"Medium","gaps":["Full-length receptor complex structure not determined","Source is a compiled review rather than a single primary structure paper"]},{"year":2006,"claim":"Showed G-CSF induces functional E-selectin ligands on myeloid cells by upregulating glycosyltransferases, linking the cytokine to adhesion under physiologic flow.","evidence":"Parallel-plate flow assay, intravital microscopy, enzymatic ablation, glycosyltransferase RT-PCR on human bone marrow cells","pmids":["16980970"],"confidence":"High","gaps":["Signaling pathway from G-CSFR to glycosyltransferase transcription not mapped"]},{"year":2006,"claim":"Distinguished an ERK-dependent, JAK/STAT-independent neuroprotective mode of G-CSF in dopaminergic neurons.","evidence":"Primary mesencephalic cultures, 6-OHDA model, MEK/ERK inhibitor, Bad/Bcl-xL/caspase-3 Western blots","pmids":["16839644"],"confidence":"Medium","gaps":["No genetic receptor knockout confirmation","Single-lab pharmacological dissection"]},{"year":2008,"claim":"Identified Gab2 Tyr643 as the Jak2-phosphorylated docking site that recruits Shp2 to drive ERK activation and proliferation, providing the link between receptor Jaks and the Ras-ERK arm.","evidence":"JAK inhibitor, Jak2 antisense/dominant-negative, in vitro Jak2 kinase assay, Gab2 Tyr643 mutagenesis, proliferation assays","pmids":["18644434"],"confidence":"High","gaps":["How Gab2 is recruited to the receptor complex not defined"]},{"year":2008,"claim":"Defined an inflammatory transcriptional input to CSF3, showing SAA induces G-CSF via TLR2/NF-κB binding to the promoter CK-1 element.","evidence":"TLR2-knockout macrophages, anti-TLR2 blockade, NF-κB assay, promoter ChIP, in vivo SAA injection","pmids":["18952897"],"confidence":"High","gaps":["Physiological settings where SAA drives G-CSF in vivo not delineated"]},{"year":2010,"claim":"Placed Gfi1-driven RasGRP1 transcription as a selective requirement for G-CSF-induced ERK activation and granulocytic differentiation, and positioned G-CSF upstream of IL-21/IL-17 in Th17 differentiation.","evidence":"Gfi1-knockout mice with RasGRP1 rescue; transplantation model with IL-21/IL-17A knockout and cytokine staining","pmids":["20203268","20435882"],"confidence":"High","gaps":["Mechanism connecting G-CSF to IL-21 induction in T cells not resolved"]},{"year":2011,"claim":"Showed G-CSF activates Lyn through Gab2-recruited Shp2 dephosphorylating inhibitory Tyr507, and established a receptor-dependent role for G-CSF in skeletal muscle myoblast proliferation and regeneration.","evidence":"Co-IP, in vitro phosphatase assays, Shp2-deficient cells, Gab2 mutants; G-CSFR-knockout mice, neutralizing antibody, BrdU assay, muscle injury model","pmids":["21636860","21422169"],"confidence":"High","gaps":["Functional consequence of Lyn activation for myeloid outcomes not fully defined","Muscle-cell-intrinsic signaling pathway downstream of CSF3R not detailed"]},{"year":2011,"claim":"Demonstrated G-CSF corrects neutrophil apoptosis and energy homeostasis in G6PC3 deficiency, linking the cytokine to metabolic and survival rescue in congenital neutropenia.","evidence":"G6pc3-knockout mice, in vivo G-CSF therapy, p-Akt/caspase-3 blots, glucose uptake and metabolite measurement","pmids":["21292774"],"confidence":"Medium","gaps":["Direct mechanistic link between CSF3R signaling and metabolite changes not established","Single-lab in vivo study"]},{"year":2014,"claim":"Established a PI3K/Akt–GSK-3β neuroprotective axis for G-CSF after neonatal hypoxia-ischemia that strictly requires CSF3R.","evidence":"Neonatal rat HI model, G-CSFR and GSK-3β siRNA, Wortmannin, TUNEL and Western blots","pmids":["25448005"],"confidence":"Medium","gaps":["No genetic knockout; reliance on siRNA and pharmacology","Single-lab study"]},{"year":2015,"claim":"Identified autophagy as a specific downstream requirement for G-CSF-driven neutrophil and HSC mobilization, distinct from CXCR4-antagonist mobilization.","evidence":"Autophagy-deficient mice, G-CSF vs AMD3100 comparison, flow cytometry and autophagy flux assays in mouse and human cells","pmids":["25788702"],"confidence":"High","gaps":["Molecular link between CSF3R signaling and autophagy induction not defined"]},{"year":2015,"claim":"Defined PLCγ2 as upstream of JAK/STAT3 and PU.1 in G-CSF-induced granulopoiesis, and showed G-CSF supports satellite-cell-dependent muscle regeneration in dystrophy models.","evidence":"PLCγ2 shRNA and inhibitors with JAK1/STAT3/PU.1 blots and CFU assays; ex vivo fiber culture and in vivo treatment of mdx/DMD mice","pmids":["24038146","25865621"],"confidence":"Medium","gaps":["How PLCγ2 is positioned relative to box1/Jak activation not reconciled","Satellite-cell-intrinsic signaling not dissected"]},{"year":2015,"claim":"Revealed a STAT3-mediated feed-forward loop by which G-CSF maintains cancer stem-cell subpopulations and upregulates its own receptor in neuroblastoma.","evidence":"CSC expansion assays, xenograft and murine tumor models, anti-G-CSF antibody, STAT3 inhibitor, G-CSFR transcriptional reporter","pmids":["25908586"],"confidence":"High","gaps":["Generality of the feed-forward loop across other tumor types not established"]},{"year":2015,"claim":"Showed LPS induces CSF3 transcription specifically through ERK2 (not ERK1), with C/EBPβ and NF-κB recruitment enabled by ERK2-driven chromatin remodeling.","evidence":"Isoform-specific ERK1/ERK2 shRNA, promoter-luciferase reporter, ChIP, DNase I accessibility assay","pmids":["26114754"],"confidence":"High","gaps":["How ERK2 selectively engages the promoter versus ERK1 not explained"]},{"year":2018,"claim":"Identified IFNγ-induced SOCS3 as a negative regulator of G-CSF-driven neutrophil expansion, with G-CSF (not GM-CSF) specifically sustaining neutrophil survival.","evidence":"IFNγ-knockout mice, G-CSF/GM-CSF depletion antibodies, SOCS3 measurement, neutrophil apoptosis assays","pmids":["29352287"],"confidence":"Medium","gaps":["Cell-type source of IFNγ-SOCS3 crosstalk in vivo not fully resolved","Single-lab study"]},{"year":2019,"claim":"Connected tissue injury to emergency hematopoiesis through an IL-1/MyD88 pathway driving G-CSF production that expands HSC/MPP and myeloid-skewed progenitors, and showed G-CSF mediates osteoblast-suppressive bone loss during S. aureus infection.","evidence":"Polytrauma model with IL-1R/MyD88-knockout mice and G-CSF ELISA; S. aureus infection model with G-CSF ELISA, neutralizing antibody, microCT","pmids":["30988118","31175224"],"confidence":"Medium","gaps":["Direct cellular source of G-CSF in each setting not fully resolved","Single-lab studies"]},{"year":2020,"claim":"Showed cancer-associated adipocyte-derived G-CSF promotes breast cancer invasion through STAT3-driven MMP2/MMP9 expression, extending the tumor-promoting STAT3 axis to the stromal microenvironment.","evidence":"Primary cancer-associated adipocytes, recombinant G-CSF, neutralizing antibody, Stat3 siRNA/inhibitor, migration/invasion assays, transcriptomics","pmids":["32242230"],"confidence":"Medium","gaps":["In vivo contribution of adipocyte-derived G-CSF to metastasis not tested","Single-lab study"]},{"year":2023,"claim":"Established G-CSF as the key pathogenic driver of APLAID autoinflammation, with anti-G-CSF antibody fully reversing disease and bone marrow transplant identifying a non-hematopoietic G-CSF source.","evidence":"APLAID PLCG2 knock-in mice, anti-G-CSF antibody, bone marrow transplantation, cytokine profiling, flow cytometry","pmids":["36997670"],"confidence":"High","gaps":["Identity of the non-hematopoietic G-CSF-producing cell not defined","Translation to human APLAID untested in this work"]},{"year":null,"claim":"How CSF3R endosomal trafficking, ubiquitination and redox-controlled phosphatase activity quantitatively tune signal amplitude and the switch from proliferation to differentiation remains unresolved at the molecular level.","evidence":"","pmids":[],"confidence":"Low","gaps":["Mechanistic detail rests on a review without new primary experiments [#26]","Specific ubiquitin ligases and endosomal phosphatases not identified","Link between receptor routing and downstream STAT/ERK balance not directly demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[11,12]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,11,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,4]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13,21,22,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,9,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,22,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[13,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[15,16]}],"complexes":[],"partners":["CSF3R","JAK2","STAT3","GAB2","PTPN11","LYN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09919","full_name":"Granulocyte colony-stimulating factor","aliases":["Pluripoietin"],"length_aa":207,"mass_kda":22.3,"function":"Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P09919/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSF3","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CSF3","total_profiled":1310},"omim":[{"mim_id":"621133","title":"OPIOID GROWTH FACTOR RECEPTOR-LIKE PROTEIN 1; OGFRL1","url":"https://www.omim.org/entry/621133"},{"mim_id":"616115","title":"FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 4; FCAS4","url":"https://www.omim.org/entry/616115"},{"mim_id":"616022","title":"NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE; SCN6","url":"https://www.omim.org/entry/616022"},{"mim_id":"616012","title":"JAGUNAL HOMOLOG 1; JAGN1","url":"https://www.omim.org/entry/616012"},{"mim_id":"615712","title":"OTU DEUBIQUITINASE WITH LINEAR LINKAGE SPECIFICITY; OTULIN","url":"https://www.omim.org/entry/615712"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":142.1},{"tissue":"urinary bladder","ntpm":53.4}],"url":"https://www.proteinatlas.org/search/CSF3"},"hgnc":{"alias_symbol":["MGC45931"],"prev_symbol":["GCSF","G-CSF","C17orf33"]},"alphafold":{"accession":"P09919","domains":[{"cath_id":"1.20.1250.10","chopping":"42-206","consensus_level":"high","plddt":90.6168,"start":42,"end":206}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09919","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09919-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09919-F1-predicted_aligned_error_v6.png","plddt_mean":84.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSF3","jax_strain_url":"https://www.jax.org/strain/search?query=CSF3"},"sequence":{"accession":"P09919","fasta_url":"https://rest.uniprot.org/uniprotkb/P09919.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09919/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09919"}},"corpus_meta":[{"pmid":"15723072","id":"PMC_15723072","title":"G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15723072","citation_count":474,"is_preprint":false},{"pmid":"16037394","id":"PMC_16037394","title":"G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16037394","citation_count":403,"is_preprint":false},{"pmid":"26254266","id":"PMC_26254266","title":"G-CSF and GM-CSF in Neutropenia.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26254266","citation_count":291,"is_preprint":false},{"pmid":"16019425","id":"PMC_16019425","title":"G-CSF: a key regulator of neutrophil production, but that's not all!","date":"2005","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/16019425","citation_count":280,"is_preprint":false},{"pmid":"25131807","id":"PMC_25131807","title":"G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25131807","citation_count":251,"is_preprint":false},{"pmid":"16537807","id":"PMC_16537807","title":"G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16537807","citation_count":188,"is_preprint":false},{"pmid":"20435882","id":"PMC_20435882","title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20435882","citation_count":142,"is_preprint":false},{"pmid":"18952897","id":"PMC_18952897","title":"Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18952897","citation_count":140,"is_preprint":false},{"pmid":"19798030","id":"PMC_19798030","title":"G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis.","date":"2009","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19798030","citation_count":135,"is_preprint":false},{"pmid":"20237318","id":"PMC_20237318","title":"G-CSF and its receptor in myeloid malignancy.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20237318","citation_count":126,"is_preprint":false},{"pmid":"34728120","id":"PMC_34728120","title":"G-CSF - A double edge sword in neutrophil mediated immunity.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34728120","citation_count":117,"is_preprint":false},{"pmid":"16224535","id":"PMC_16224535","title":"NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16224535","citation_count":105,"is_preprint":false},{"pmid":"16051386","id":"PMC_16051386","title":"Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction.","date":"2005","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/16051386","citation_count":103,"is_preprint":false},{"pmid":"11823538","id":"PMC_11823538","title":"G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11823538","citation_count":91,"is_preprint":false},{"pmid":"16141785","id":"PMC_16141785","title":"G-CSF suppresses edema formation and reduces interleukin-1beta expression after cerebral ischemia in mice.","date":"2005","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16141785","citation_count":90,"is_preprint":false},{"pmid":"12060844","id":"PMC_12060844","title":"G-CSF: function and modes of action (Review).","date":"2002","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12060844","citation_count":86,"is_preprint":false},{"pmid":"33677228","id":"PMC_33677228","title":"G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/33677228","citation_count":85,"is_preprint":false},{"pmid":"35843375","id":"PMC_35843375","title":"Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35843375","citation_count":84,"is_preprint":false},{"pmid":"16380448","id":"PMC_16380448","title":"Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16380448","citation_count":82,"is_preprint":false},{"pmid":"12005202","id":"PMC_12005202","title":"Molecular aspects of anti-inflammatory action of G-CSF.","date":"2002","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/12005202","citation_count":81,"is_preprint":false},{"pmid":"25908586","id":"PMC_25908586","title":"G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25908586","citation_count":80,"is_preprint":false},{"pmid":"16807060","id":"PMC_16807060","title":"The role of G-CSF in adaptive immunity.","date":"2006","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16807060","citation_count":77,"is_preprint":false},{"pmid":"21422169","id":"PMC_21422169","title":"G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21422169","citation_count":74,"is_preprint":false},{"pmid":"25834108","id":"PMC_25834108","title":"G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25834108","citation_count":72,"is_preprint":false},{"pmid":"7539779","id":"PMC_7539779","title":"The effect of GM-CSF and G-CSF on human neutrophil function.","date":"1995","source":"Immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7539779","citation_count":72,"is_preprint":false},{"pmid":"16239431","id":"PMC_16239431","title":"Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16239431","citation_count":70,"is_preprint":false},{"pmid":"34772606","id":"PMC_34772606","title":"G-CSF, the guardian of granulopoiesis.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34772606","citation_count":69,"is_preprint":false},{"pmid":"16964312","id":"PMC_16964312","title":"CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16964312","citation_count":69,"is_preprint":false},{"pmid":"1689760","id":"PMC_1689760","title":"Differential expression of M-CSF, G-CSF, and GM-CSF by human monocytes.","date":"1990","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/1689760","citation_count":67,"is_preprint":false},{"pmid":"15069015","id":"PMC_15069015","title":"G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15069015","citation_count":65,"is_preprint":false},{"pmid":"21685373","id":"PMC_21685373","title":"G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21685373","citation_count":58,"is_preprint":false},{"pmid":"18205701","id":"PMC_18205701","title":"Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection.","date":"2007","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18205701","citation_count":56,"is_preprint":false},{"pmid":"24179471","id":"PMC_24179471","title":"G-CSF in Healthy Allogeneic Stem Cell Donors.","date":"2013","source":"Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie","url":"https://pubmed.ncbi.nlm.nih.gov/24179471","citation_count":56,"is_preprint":false},{"pmid":"19363527","id":"PMC_19363527","title":"Optimal use of G-CSF administration after hematopoietic SCT.","date":"2009","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19363527","citation_count":54,"is_preprint":false},{"pmid":"15671148","id":"PMC_15671148","title":"Roles of Stat3 and ERK in G-CSF signaling.","date":"2005","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/15671148","citation_count":53,"is_preprint":false},{"pmid":"24416642","id":"PMC_24416642","title":"SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24416642","citation_count":51,"is_preprint":false},{"pmid":"19447168","id":"PMC_19447168","title":"Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF.","date":"2009","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19447168","citation_count":50,"is_preprint":false},{"pmid":"32242230","id":"PMC_32242230","title":"Cancer-associated adipocyte-derived G-CSF promotes breast cancer malignancy via Stat3 signaling.","date":"2020","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32242230","citation_count":48,"is_preprint":false},{"pmid":"24707817","id":"PMC_24707817","title":"G-CSF: filgrastim, lenograstim and biosimilars.","date":"2014","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24707817","citation_count":47,"is_preprint":false},{"pmid":"19345152","id":"PMC_19345152","title":"G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo.","date":"2009","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/19345152","citation_count":47,"is_preprint":false},{"pmid":"25804941","id":"PMC_25804941","title":"Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25804941","citation_count":45,"is_preprint":false},{"pmid":"16418824","id":"PMC_16418824","title":"Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/16418824","citation_count":44,"is_preprint":false},{"pmid":"25865621","id":"PMC_25865621","title":"G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25865621","citation_count":44,"is_preprint":false},{"pmid":"16839644","id":"PMC_16839644","title":"G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway.","date":"2006","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/16839644","citation_count":44,"is_preprint":false},{"pmid":"21292774","id":"PMC_21292774","title":"G-CSF improves murine G6PC3-deficient neutrophil function by modulating apoptosis and energy homeostasis.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21292774","citation_count":44,"is_preprint":false},{"pmid":"11368439","id":"PMC_11368439","title":"C/EBPalpha and G-CSF receptor signals cooperate to induce the myeloperoxidase and neutrophil elastase genes.","date":"2001","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/11368439","citation_count":44,"is_preprint":false},{"pmid":"16980970","id":"PMC_16980970","title":"G-CSF induces E-selectin ligand expression on human myeloid cells.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16980970","citation_count":43,"is_preprint":false},{"pmid":"20203268","id":"PMC_20203268","title":"The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20203268","citation_count":43,"is_preprint":false},{"pmid":"34763974","id":"PMC_34763974","title":"Immunomodulatory effects of G-CSF in cancer: Therapeutic implications.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34763974","citation_count":42,"is_preprint":false},{"pmid":"20851808","id":"PMC_20851808","title":"G-CSF for stem cell therapy in acute myocardial infarction: friend or foe?","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20851808","citation_count":42,"is_preprint":false},{"pmid":"33389706","id":"PMC_33389706","title":"Neuroprotection through G-CSF: recent advances and future viewpoints.","date":"2021","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/33389706","citation_count":41,"is_preprint":false},{"pmid":"2473663","id":"PMC_2473663","title":"Review of G-CSF and GM-CSF. Effects on neonatal neutrophil kinetics.","date":"1989","source":"The American journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/2473663","citation_count":40,"is_preprint":false},{"pmid":"25788702","id":"PMC_25788702","title":"Autophagy is required for stem cell mobilization by G-CSF.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25788702","citation_count":40,"is_preprint":false},{"pmid":"9374735","id":"PMC_9374735","title":"Hemorrhagic shock induces G-CSF expression in bronchial epithelium.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9374735","citation_count":40,"is_preprint":false},{"pmid":"17888521","id":"PMC_17888521","title":"G-CSF therapy for acute myocardial infarction.","date":"2007","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17888521","citation_count":39,"is_preprint":false},{"pmid":"24844175","id":"PMC_24844175","title":"Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor.","date":"2014","source":"Journal of neurosurgical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24844175","citation_count":38,"is_preprint":false},{"pmid":"32601321","id":"PMC_32601321","title":"G-CSF Inhibits Pulmonary Fibrosis by Promoting BMSC Homing to the Lungs via SDF-1/CXCR4 Chemotaxis.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32601321","citation_count":37,"is_preprint":false},{"pmid":"21745453","id":"PMC_21745453","title":"Can G-CSF cause leukemia in hematopoietic stem cell donors?","date":"2011","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21745453","citation_count":35,"is_preprint":false},{"pmid":"28320832","id":"PMC_28320832","title":"G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28320832","citation_count":33,"is_preprint":false},{"pmid":"17223129","id":"PMC_17223129","title":"G-CSF and HGF: combination of vasculogenesis and angiogenesis synergistically improves recovery in murine hind limb ischemia.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17223129","citation_count":33,"is_preprint":false},{"pmid":"16720384","id":"PMC_16720384","title":"The interaction of G-CSF with its receptor.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16720384","citation_count":32,"is_preprint":false},{"pmid":"33036138","id":"PMC_33036138","title":"G-CSF and G-CSFR Induce a Pro-Tumorigenic Macrophage Phenotype to Promote Colon and Pancreas Tumor Growth.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33036138","citation_count":32,"is_preprint":false},{"pmid":"9015216","id":"PMC_9015216","title":"Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils.","date":"1997","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9015216","citation_count":32,"is_preprint":false},{"pmid":"25448005","id":"PMC_25448005","title":"G-CSF ameliorates neuronal apoptosis through GSK-3β inhibition in neonatal hypoxia-ischemia in rats.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25448005","citation_count":32,"is_preprint":false},{"pmid":"18393854","id":"PMC_18393854","title":"Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications.","date":"2008","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18393854","citation_count":31,"is_preprint":false},{"pmid":"9681250","id":"PMC_9681250","title":"G-CSF production in human bladder cancer and its ability to promote autocrine growth: a review.","date":"1998","source":"Cytokines, cellular & molecular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/9681250","citation_count":31,"is_preprint":false},{"pmid":"33737338","id":"PMC_33737338","title":"Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33737338","citation_count":31,"is_preprint":false},{"pmid":"20382196","id":"PMC_20382196","title":"Serum IL-7 and G-CSF in major depressive disorder.","date":"2010","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20382196","citation_count":31,"is_preprint":false},{"pmid":"26524416","id":"PMC_26524416","title":"G-CSF promotes autophagy and reduces neural tissue damage after spinal cord injury in mice.","date":"2015","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26524416","citation_count":31,"is_preprint":false},{"pmid":"25867648","id":"PMC_25867648","title":"Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.","date":"2015","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/25867648","citation_count":31,"is_preprint":false},{"pmid":"21636860","id":"PMC_21636860","title":"G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21636860","citation_count":31,"is_preprint":false},{"pmid":"18536571","id":"PMC_18536571","title":"G-CSF receptor mutations in patients with congenital neutropenia.","date":"2008","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18536571","citation_count":31,"is_preprint":false},{"pmid":"26482176","id":"PMC_26482176","title":"Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.","date":"2015","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/26482176","citation_count":30,"is_preprint":false},{"pmid":"30988118","id":"PMC_30988118","title":"Trauma Induces Emergency Hematopoiesis through IL-1/MyD88-Dependent Production of G-CSF.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30988118","citation_count":30,"is_preprint":false},{"pmid":"21358682","id":"PMC_21358682","title":"G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.","date":"2011","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21358682","citation_count":29,"is_preprint":false},{"pmid":"26114754","id":"PMC_26114754","title":"LPS-Induced G-CSF Expression in Macrophages Is Mediated by ERK2, but Not ERK1.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26114754","citation_count":28,"is_preprint":false},{"pmid":"22846180","id":"PMC_22846180","title":"Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.","date":"2012","source":"Theoretical biology & medical modelling","url":"https://pubmed.ncbi.nlm.nih.gov/22846180","citation_count":27,"is_preprint":false},{"pmid":"24038146","id":"PMC_24038146","title":"PLCγ2 and PKC are important to myeloid lineage commitment triggered by M-SCF and G-CSF.","date":"2014","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24038146","citation_count":27,"is_preprint":false},{"pmid":"28881590","id":"PMC_28881590","title":"Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881590","citation_count":26,"is_preprint":false},{"pmid":"34049929","id":"PMC_34049929","title":"G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34049929","citation_count":25,"is_preprint":false},{"pmid":"30916396","id":"PMC_30916396","title":"G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients.","date":"2019","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/30916396","citation_count":25,"is_preprint":false},{"pmid":"21623923","id":"PMC_21623923","title":"G-CSF enhances the proliferation and mobilization, but not the maturation rate, of murine myeloid cells.","date":"2011","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/21623923","citation_count":25,"is_preprint":false},{"pmid":"11240647","id":"PMC_11240647","title":"G-CSF receptor expression in ovarian cancer.","date":"2000","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/11240647","citation_count":24,"is_preprint":false},{"pmid":"17379064","id":"PMC_17379064","title":"Growth factors G-CSF and GM-CSF differentially preserve chemotaxis of neutrophils aging in vitro.","date":"2007","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17379064","citation_count":24,"is_preprint":false},{"pmid":"10214858","id":"PMC_10214858","title":"Cell lineage specificity in G-CSF receptor gene methylation.","date":"1999","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/10214858","citation_count":23,"is_preprint":false},{"pmid":"23276911","id":"PMC_23276911","title":"Scratching the surface: signaling and routing dynamics of the CSF3 receptor.","date":"2013","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/23276911","citation_count":22,"is_preprint":false},{"pmid":"24073859","id":"PMC_24073859","title":"New G-CSF agonists for neutropenia therapy.","date":"2013","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24073859","citation_count":22,"is_preprint":false},{"pmid":"26718978","id":"PMC_26718978","title":"G-CSF and Neutrophils Are Nonredundant Mediators of Murine Experimental Autoimmune Uveoretinitis.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26718978","citation_count":22,"is_preprint":false},{"pmid":"18644434","id":"PMC_18644434","title":"G-CSF stimulates Jak2-dependent Gab2 phosphorylation leading to Erk1/2 activation and cell proliferation.","date":"2008","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18644434","citation_count":22,"is_preprint":false},{"pmid":"29352287","id":"PMC_29352287","title":"IFNγ inhibits G-CSF induced neutrophil expansion and invasion of the CNS to prevent viral encephalitis.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29352287","citation_count":22,"is_preprint":false},{"pmid":"22252524","id":"PMC_22252524","title":"Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22252524","citation_count":22,"is_preprint":false},{"pmid":"36997670","id":"PMC_36997670","title":"G-CSF drives autoinflammation in APLAID.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36997670","citation_count":20,"is_preprint":false},{"pmid":"33848847","id":"PMC_33848847","title":"G-CSF promotes alloregulatory function of MDSCs through a c-Kit dependent mechanism.","date":"2021","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33848847","citation_count":20,"is_preprint":false},{"pmid":"17127394","id":"PMC_17127394","title":"Src kinases in G-CSF receptor signaling.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127394","citation_count":19,"is_preprint":false},{"pmid":"32092138","id":"PMC_32092138","title":"Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32092138","citation_count":19,"is_preprint":false},{"pmid":"22890921","id":"PMC_22890921","title":"Hematopoietic stem cell mobilization with agents other than G-CSF.","date":"2012","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/22890921","citation_count":19,"is_preprint":false},{"pmid":"31495390","id":"PMC_31495390","title":"Vildagliptin and G-CSF Improved Angiogenesis and Survival after Acute Myocardial Infarction.","date":"2019","source":"Archives of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/31495390","citation_count":18,"is_preprint":false},{"pmid":"31175224","id":"PMC_31175224","title":"G-CSF partially mediates bone loss induced by Staphylococcus aureus infection in mice.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31175224","citation_count":18,"is_preprint":false},{"pmid":"30283148","id":"PMC_30283148","title":"Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation.","date":"2018","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/30283148","citation_count":18,"is_preprint":false},{"pmid":"20354107","id":"PMC_20354107","title":"Systemic levels of G-CSF and interleukin-6 determine the angiogenic potential of bone marrow resident monocytes.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20354107","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47081,"output_tokens":7889,"usd":0.129789,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17425,"output_tokens":7079,"usd":0.13205,"stage2_stop_reason":"end_turn"},"total_usd":0.261839,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"G-CSF acts directly on cardiomyocytes by binding the G-CSF receptor expressed on their surface, activating the JAK/STAT3 pathway, inducing antiapoptotic proteins, inhibiting cardiomyocyte apoptosis, and reducing endothelial cell apoptosis; all these effects were abolished by overexpression of a dominant-negative STAT3 mutant in cardiomyocytes.\",\n      \"method\": \"Dominant-negative STAT3 transgenic overexpression in cardiomyocytes; in vivo myocardial infarction model; immunostaining and apoptosis assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative genetic rescue experiment with defined molecular pathway, rigorous loss-of-function controls, replicated across multiple outcome measures in vivo\",\n      \"pmids\": [\"15723072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"G-CSF down-regulates CXCR4 expression on bone marrow Gr1+ myeloid cells in a cell-autonomous manner (G-CSF receptor is expressed on these cells), thereby attenuating SDF-1/CXCR4-mediated retention and promoting myeloid cell mobilization from bone marrow to peripheral blood.\",\n      \"method\": \"Flow cytometry of purified Gr1+ bone marrow cells treated with G-CSF in vitro; migration and attachment assays with SDF-1; in vivo G-CSF mobilization in mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional assays on purified cells plus corroborating in vivo model, two orthogonal methods (surface CXCR4 measurement + migration assay)\",\n      \"pmids\": [\"16537807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"G-CSF treatment potently inhibits osteoblast activity (measured by histomorphometry and osteocalcin expression) and decreases CXCL12 mRNA and protein in bone marrow through an indirect mechanism, since the G-CSF receptor is not expressed on osteoblasts; reduced CXCL12/CXCR4 signaling leads to hematopoietic progenitor cell mobilization.\",\n      \"method\": \"Transgenic mice with targeted G-CSF receptor mutations; histomorphometry; CXCL12 mRNA and protein measurement; cell sorting to identify CXCL12-producing cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple receptor mutant mouse lines with graded mobilization phenotypes correlated to CXCL12 levels, cell-type-specific receptor absence confirmed, multiple orthogonal methods\",\n      \"pmids\": [\"16037394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Truncated G-CSF receptor mutants (found in SCN/AML) lose the SOCS3 recruitment site Tyr729 and show defective receptor internalization, resulting in reduced SOCS3 expression and loss of SOCS3-mediated STAT5 inhibition while STAT3 inhibition remains intact, leading to an increased STAT5/STAT3 activation ratio and hyperproliferative responses to G-CSF.\",\n      \"method\": \"Luciferase reporter assays for STAT3/STAT5 activation; SOCS3 expression measurement in bone marrow of gcsfr-d715 mice; receptor internalization assays; site-directed mutagenesis of Tyr729\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis identifying specific tyrosine residue, reporter assays, corroborated in mouse model, multiple orthogonal methods\",\n      \"pmids\": [\"15069015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"STAT3 functions as a negative regulator of G-CSF signaling by inducing SOCS3 expression; in Stat3-deficient hematopoietic cells, SOCS3 expression is nearly absent, ERK1/2 activation is enhanced and sustained, and the augmented G-CSF-induced proliferation is abrogated by MEK1 inhibition, identifying ERK as the major driver of proliferation downstream of G-CSF when STAT3 is absent.\",\n      \"method\": \"Conditional Stat3-knockout mice in hematopoietic cells; MEK1 inhibitor treatment; Western blotting for ERK and SOCS3; bone marrow colony assays\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function mouse model plus pharmacological rescue, multiple downstream readouts, clear epistasis established\",\n      \"pmids\": [\"15671148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF induces expression of E-selectin ligands HCELL and an ~65 kDa ligand on myeloid cells by upregulating glycosyltransferases (ST3GalIV, FucT-IV, FucT-VII), leading to heightened myeloid cell adhesion to inflamed endothelium under physiologic flow conditions.\",\n      \"method\": \"Parallel plate flow assay; intravital microscopy; enzymatic treatments; biochemical characterization of E-selectin ligands; RT-PCR for glycosyltransferases; in vitro G-CSF treatment of normal human bone marrow cells\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (flow assay, intravital microscopy, enzymatic ablation, gene expression), direct mechanistic link from glycosyltransferase induction to functional adhesion\",\n      \"pmids\": [\"16980970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"G-CSF promotes Th17 differentiation (amplifying IL-17 production in CD4 and CD8 T cells) through a mechanism dependent on and downstream of G-CSF-induced IL-21 signaling; donor IL-17A controls macrophage infiltration into skin and cutaneous fibrosis after transplantation.\",\n      \"method\": \"Murine hematopoietic transplantation model; cytokine blocking/knockout mice (IL-17A, IL-21); intracellular cytokine staining; flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (IL-21 and IL-17A knockout) placing G-CSF upstream of IL-21 and IL-17 in a defined pathway, replicated with multiple cytokine interventions\",\n      \"pmids\": [\"20435882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"G-CSF transcription factor Gfi1 regulates G-CSF-induced Erk1/2 activation and granulocytic differentiation through transcriptional control of the Ras activator RasGRP1; Gfi1-null myeloid cells selectively fail to activate Erk1/2 (but not STAT1/3) in response to G-CSF, and forced RasGRP1 expression rescues this defect.\",\n      \"method\": \"Gfi1-knockout mice; retroviral RasGRP1 transduction rescue experiment; Western blotting for Erk1/2, STAT1, STAT3 activation; colony assays; RT-PCR\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with selective signaling defect identified, epistasis confirmed by rescue experiment, two orthogonal methods\",\n      \"pmids\": [\"20203268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF activates Lyn (the predominant Src kinase in myeloid cells) through Gab2-mediated recruitment of the Shp2 phosphatase, which dephosphorylates inhibitory phospho-Tyr507 on Lyn; Gab2 Tyr507 dephosphorylation was abrogated in Shp2-deficient cells and by Gab2 mutations preventing Shp2 binding.\",\n      \"method\": \"Co-immunoprecipitation; in vitro kinase/phosphatase assays with purified proteins; Shp2-deficient cells; Gab2 mutants; siRNA knockdown of Gab2\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro reconstitution of phosphatase activity on specific tyrosine residue plus mutagenesis and genetic KO, multiple orthogonal methods\",\n      \"pmids\": [\"21636860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"G-CSF stimulates Jak2-dependent phosphorylation of Gab2 at Tyr643, which recruits Shp2 and leads to Erk1/2 activation and cell proliferation; mutation of Gab2 Tyr643 inhibited G-CSF-stimulated Erk1/2 activation, Shp2 binding, and Gab2-mediated proliferation.\",\n      \"method\": \"JAK inhibitor treatment; Jak2 antisense and dominant-negative constructs; in vitro kinase assay with activated Jak2; Gab2 site-directed mutagenesis; cell proliferation assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro reconstitution with Jak2 phosphorylating Gab2, site-directed mutagenesis confirming key residue, multiple orthogonal approaches\",\n      \"pmids\": [\"18644434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"G-CSF receptor signals cooperate with C/EBPα to induce myeloperoxidase (MPO) and neutrophil elastase (NE) gene expression; receptor tyrosine mutations revealed that all four cytoplasmic tyrosines are required for NE induction, while mutation of Tyr704 specifically enhanced MPO induction, indicating distinct tyrosine requirements for different myeloid differentiation genes.\",\n      \"method\": \"Ba/F3 cells co-expressing C/EBPα-ER and G-CSF receptor mutants; RT-PCR for MPO, NE, LF, PU.1; tyrosine-to-alanine mutant receptors\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — systematic site-directed mutagenesis of receptor tyrosines with gene expression readouts, reconstitution in defined cell line\",\n      \"pmids\": [\"11368439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The G-CSF receptor requires the membrane-proximal box 1 PDP (PXP) motif for activation of Jak1, Jak2, and Tyk2, tyrosine phosphorylation of the receptor, and STAT3/STAT1 recruitment; Jak kinases are not activated in terminally differentiated neutrophils upon G-CSF stimulation, indicating utilization of alternative signaling pathways in mature cells.\",\n      \"method\": \"G-CSF receptor Pro639Ala/Pro641Ala mutant transfected into Ba/F3 and NFS-60 cells; kinase immunoprecipitation and phosphorylation assays; comparison between proliferating cell lines and primary neutrophils\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — site-directed mutagenesis identifying required motif, compared in proliferating vs. terminally differentiated primary cells, multiple kinases assessed\",\n      \"pmids\": [\"9015216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The G-CSF receptor complex has 2:2 stoichiometry with two binding sites on both ligand and receptor equivalent to site II and site III of the IL-6 receptor complex; structure of the ligand-binding domain was determined by crystallography in complex with G-CSF.\",\n      \"method\": \"Crystal structure of partial ligand-receptor complex; mutagenesis of receptor and ligand; neutralizing antibody mapping; solution-phase binding studies\",\n      \"journal\": \"Frontiers in bioscience : a journal and virtual library\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus mutagenesis reported, but this is a review compiling multiple prior studies, not a single primary paper; confidence moderate given secondary synthesis\",\n      \"pmids\": [\"16720384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Serum amyloid A (SAA) induces G-CSF gene expression in macrophages via Toll-like receptor 2 (TLR2); SAA stimulation activates NF-κB and promotes binding to the CK-1 element of the G-CSF promoter; this effect is blocked by anti-TLR2 antibody and absent in TLR2-deficient macrophages.\",\n      \"method\": \"TLR2-knockout macrophages; anti-TLR2 antibody blockade; NF-κB activation assay; chromatin immunoprecipitation (promoter binding); in vitro reconstitution; in vivo SAA injection in wild-type vs. G-CSF- or TLR2-deficient mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO macrophages, antibody blockade, ChIP assay, and in vivo rescue, multiple orthogonal methods confirming TLR2→NF-κB→G-CSF promoter pathway\",\n      \"pmids\": [\"18952897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G-CSF selectively activates STAT3 within neuroblastoma cancer stem cell (CSC) subpopulations via G-CSF receptor; STAT3 acts in a feed-forward loop to transcriptionally activate G-CSF receptor expression; blockade with anti-G-CSF antibody or STAT3 inhibitor depleted CSC subpopulation, inhibited tumor growth, decreased metastasis, and increased chemosensitivity.\",\n      \"method\": \"In vitro CSC expansion assays; human xenograft and murine neuroblastoma tumor models; anti-G-CSF antibody blockade; STAT3 inhibitor; reporter assays for G-CSFR transcription\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two in vivo tumor models plus in vitro mechanistic dissection with pharmacological blockade and antibody neutralization, feed-forward loop confirmed by transcriptional reporter\",\n      \"pmids\": [\"25908586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF receptor (G-CSFR) is expressed on myoblasts during embryonic development and transiently on regenerating myocytes in injured adult skeletal muscle; neutralization of endogenous G-CSF impairs muscle regeneration, exogenous G-CSF promotes myoblast proliferation, and muscle regeneration is markedly impaired in G-CSFR-knockout mice.\",\n      \"method\": \"G-CSFR-knockout mice; G-CSF neutralizing antibody; BrdU proliferation assay; in vivo muscle injury model; immunostaining\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor KO, antibody neutralization, and exogenous cytokine rescue with defined proliferative readout; multiple orthogonal approaches\",\n      \"pmids\": [\"21422169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G-CSF receptor is asymmetrically expressed in activated satellite cells; G-CSF positively affects the satellite cell population during multiple differentiation stages; G-CSF supports long-term muscle regeneration, functional maintenance, and lifespan extension in mdx mouse models of Duchenne muscular dystrophy.\",\n      \"method\": \"Ex vivo fiber culture assay; immunostaining for asymmetric G-CSFR expression; in vivo G-CSF treatment of mdx and more severe DMD mouse models; functional assessments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization of receptor to satellite cells with functional consequence, multiple DMD models, ex vivo and in vivo corroboration\",\n      \"pmids\": [\"25865621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF protects dopaminergic neurons from 6-OHDA toxicity via the ERK pathway (not JAK/STAT); G-CSF activates ERK, increases phosphorylation of Bad, restores Bcl-xL levels, and inhibits caspase-3 activation; ERK inhibition abrogates all these protective effects.\",\n      \"method\": \"Primary mesencephalic cultures; 6-OHDA neurotoxicity model; Western blotting for ERK, p-Bad, Bcl-xL, caspase-3; MEK/ERK inhibitor pharmacological blockade; immunostaining\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple downstream readouts, single lab, no genetic KO confirmation\",\n      \"pmids\": [\"16839644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"G-CSF attenuates neuronal apoptosis after neonatal hypoxia-ischemia via PI3K/Akt-dependent inhibition of GSK-3β activity, reducing caspase-3 activation and increasing Bcl-2/Bax ratio; this neuroprotective effect is abolished by G-CSF receptor siRNA or PI3K inhibitor Wortmannin.\",\n      \"method\": \"Neonatal rat HI model; G-CSFR siRNA; GSK-3β siRNA; PI3K inhibitor Wortmannin; Western blotting; TUNEL assay; immunofluorescence\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-level KD confirming requirement for G-CSFR, PI3K inhibitor placing Akt upstream of GSK-3β, single lab\",\n      \"pmids\": [\"25448005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G-CSF activates autophagy in both neutrophils and hematopoietic stem cells (HSCs); G-CSF-induced neutrophil and HSC mobilization is impaired in the absence of autophagy, whereas direct HSC mobilization by the CXCR4 antagonist AMD3100 does not require autophagy, placing autophagy as a specific requirement downstream of G-CSF signaling for mobilization.\",\n      \"method\": \"Autophagy-deficient mouse models; G-CSF vs. AMD3100 mobilization comparison; flow cytometry; autophagy flux assays in murine and human donor cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic autophagy KO demonstrating G-CSF-specific requirement, negative control with AMD3100 establishing specificity, replicated in mouse and human\",\n      \"pmids\": [\"25788702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G-CSF activates PLCγ2, PKC, JAK-1, and STAT-3 in myeloid progenitors during granulocytic commitment; STAT-3 activation and increased PU.1 expression downstream of G-CSF are sensitive to PLC inhibition, placing PLCγ2 upstream of JAK/STAT and PU.1 in G-CSF-induced granulopoiesis.\",\n      \"method\": \"Flow cytometry; RNA interference (PLCγ2 shRNA); PLCγ/PKC inhibitors; Western blotting for JAK1, STAT3, PU.1; colony-forming unit assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown plus pharmacological inhibition establishing pathway hierarchy, single lab, no structural validation\",\n      \"pmids\": [\"24038146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LPS-induced G-CSF expression in macrophages is mediated specifically by ERK2 (not ERK1); ERK2 and C/EBPβ synergistically activate the G-CSF promoter; ERK2 promotes LPS-induced binding of NF-κB (p50/p65) and C/EBPβ to the G-CSF promoter through chromatin remodeling.\",\n      \"method\": \"shRNA knockdown of ERK1 vs. ERK2; G-CSF promoter-luciferase reporter assays; chromatin immunoprecipitation (ChIP); DNase I accessibility assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — isoform-specific shRNA plus ChIP and reporter assay plus chromatin remodeling assay, mechanistic pathway from ERK2 to G-CSF transcription fully demonstrated\",\n      \"pmids\": [\"26114754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tissue injury induces emergency hematopoiesis through an IL-1/MyD88-dependent pathway that drives G-CSF production; G-CSF then expands hematopoietic progenitors including HSCs and MPPs and increases myeloid-skewed progenitor frequency.\",\n      \"method\": \"Mouse polytrauma model; IL-1 receptor/MyD88-knockout mice; ELISA for G-CSF; flow cytometry of bone marrow progenitors\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO establishing IL-1/MyD88 pathway upstream of G-CSF, single lab, limited mechanistic depth beyond cytokine production\",\n      \"pmids\": [\"30988118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF improves neutrophil function in G6PC3-deficient mice by modulating apoptotic mediators (normalizing p-Akt, PI3K, and active caspase-3 levels) and rectifying energy homeostasis (increasing glucose uptake and intracellular G6P, lactate, and ATP levels) in vivo.\",\n      \"method\": \"G6pc3-knockout mice; in vivo G-CSF therapy; Western blotting for p-Akt, caspase-3; glucose uptake assay; metabolite measurement; in vitro apoptosis assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with multiple in vivo biochemical readouts, single lab\",\n      \"pmids\": [\"21292774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G-CSF is the key driver of autoinflammation in APLAID (PLCG2 gain-of-function missense mutation model); treatment with an anti-G-CSF antibody completely reversed established disease in APLAID mice, normalized myelopoiesis, and restored lymphocyte counts; bone marrow transplantation from healthy donors reduced G-CSF production (predominantly from non-hematopoietic cells) and fully rescued APLAID mice.\",\n      \"method\": \"APLAID knock-in mouse model; anti-G-CSF antibody treatment; bone marrow transplantation; cytokine profiling; flow cytometry of immune cell populations\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic disease model with antibody rescue plus bone marrow transplantation epistasis identifying non-hematopoietic source of G-CSF, multiple orthogonal interventions\",\n      \"pmids\": [\"36997670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IFNγ suppresses G-CSF signaling by increasing SOCS3 expression in neutrophils, leading to neutrophil apoptosis; depletion of G-CSF (but not GM-CSF) in IFNγ-deficient mice induces neutrophil apoptosis and restores IL-10 secretion, identifying IFNγ-SOCS3 as a negative regulator of G-CSF-driven neutrophil expansion.\",\n      \"method\": \"IFNγ-knockout mice; G-CSF or GM-CSF depletion antibodies; SOCS3 expression measurement; neutrophil apoptosis assays; cytokine profiling\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus antibody depletion establishing epistasis, cytokine specificity confirmed by GM-CSF negative control, single lab\",\n      \"pmids\": [\"29352287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CSF3R (G-CSF receptor) undergoes lysine ubiquitination and redox-controlled phosphatase-modulated signaling during endocytosis; receptor routing through signaling endosomes—where interactions with the endoplasmic reticulum occur—is a key mechanism for modulating CSF3R signal amplitude and duration leading first to myeloid progenitor proliferation and then to differentiation.\",\n      \"method\": \"Review summarizing biochemical and cell biology studies on CSF3R ubiquitination, endosomal trafficking, and phosphatase activities\",\n      \"journal\": \"Frontiers in bioscience (Landmark edition)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review article summarizing prior findings; no single new primary experiment described in the abstract\",\n      \"pmids\": [\"23276911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cancer-associated adipocyte-derived G-CSF promotes breast cancer cell migration and invasion by activating STAT3 signaling; downstream targets include MMP2 and MMP9; G-CSF-neutralizing antibody, STAT3 inhibitor, or Stat3 siRNA each abrogate CAA- or G-CSF-induced cancer cell migration and invasion.\",\n      \"method\": \"Primary cancer-associated adipocyte isolation; recombinant G-CSF treatment; G-CSF-neutralizing antibody; Stat3 siRNA; Western blotting; migration/invasion assays; transcriptome sequencing\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization, RNAi, and small-molecule inhibition converging on STAT3→MMP2/9 axis, single lab\",\n      \"pmids\": [\"32242230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G-CSF partially mediates bone loss induced by Staphylococcus aureus infection by suppressing osteoblast function; G-CSF levels are elevated in infected bone marrow (partly due to increased F4/80+ macrophages), and G-CSF neutralizing antibody treatment significantly rescues bone volume and preserves osteocalcin- and osterix-positive osteoblasts.\",\n      \"method\": \"Mouse S. aureus infection model; ELISA for G-CSF in bone marrow and serum; G-CSF neutralizing antibody; microCT; immunohistochemistry\",\n      \"journal\": \"Clinical science (London, England : 1979)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization with defined bone histological readout, macrophage source identified, single lab\",\n      \"pmids\": [\"31175224\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSF3 (G-CSF) binds its homodimeric receptor (G-CSFR/CSF3R) expressed on myeloid progenitors, mature neutrophils, and various non-hematopoietic cells, activating membrane-proximal JAK1/JAK2 via a conserved Box1 PXP motif, which phosphorylates STAT3, STAT5, Gab2 (at Tyr643), and the Src kinase Lyn (via Gab2-recruited Shp2 dephosphorylating inhibitory Tyr507), leading to downstream ERK1/2 and PI3K/Akt activation; STAT3 provides negative feedback by inducing SOCS3 (which suppresses further STAT5 and receptor signaling), while truncating receptor mutations lose this control to yield hyperactive STAT5 signaling associated with leukemic transformation; G-CSF also indirectly mobilizes hematopoietic stem and progenitor cells by suppressing osteoblast-derived CXCL12 and directly downregulating CXCR4 on myeloid cells through an autophagy-dependent mechanism; beyond hematopoiesis, G-CSF acts on cardiomyocytes, myoblasts, and neurons via the same receptor to activate JAK/STAT3, ERK, and PI3K/Akt survival pathways, promotes Th17 differentiation via IL-21 in T cells, and induces E-selectin ligand expression on myeloid cells through glycosyltransferase upregulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSF3 (G-CSF) is a secreted cytokine that signals through the G-CSF receptor (CSF3R) to drive granulopoiesis, myeloid cell mobilization and inflammation, while also exerting receptor-dependent survival effects on diverse non-hematopoietic tissues [#2, #15]. Receptor engagement is initiated through the membrane-proximal box1 PXP motif, which is required to activate Jak1, Jak2 and Tyk2 and to recruit STAT3/STAT1 to the phosphorylated receptor [#11], with the ligand-receptor complex assembling in a 2:2 stoichiometry [#12]. Downstream of the Jaks, G-CSF stimulates Jak2-dependent phosphorylation of Gab2 at Tyr643, recruiting the phosphatase Shp2 to drive Erk1/2 activation and proliferation [#9], and the same Gab2–Shp2 module activates the Src kinase Lyn by dephosphorylating its inhibitory Tyr507 [#8]; granulocytic Erk1/2 output additionally depends on Gfi1-driven transcription of the Ras activator RasGRP1 [#7] and on PLCγ2 acting upstream of JAK/STAT3 and PU.1 [#20], with C/EBPα cooperating with discrete receptor tyrosines to induce myeloperoxidase and neutrophil elastase [#10]. STAT3 imposes negative feedback by inducing SOCS3, restraining ERK and STAT5 output, and truncating SCN/AML receptor mutants that lose the Tyr729 SOCS3 site escape this control to yield a hyperproliferative high-STAT5 state [#3, #4]. In hematopoiesis G-CSF mobilizes stem/progenitor and myeloid cells both indirectly, by suppressing osteoblast-derived CXCL12 [#2], and cell-autonomously, by downregulating CXCR4 on Gr1+ cells [#1], with mobilization requiring autophagy [#19], and it enhances myeloid adhesion by inducing E-selectin ligands through glycosyltransferase upregulation [#5]. CSF3 transcription is itself driven by inflammatory inputs including SAA via TLR2/NF-κB [#13], LPS via ERK2/C/EBPβ/NF-κB chromatin remodeling [#21], and IL-1/MyD88 during emergency hematopoiesis [#22]. Beyond blood, G-CSF activates JAK/STAT3 anti-apoptotic signaling in cardiomyocytes [#0], supports myoblast and satellite-cell-dependent muscle regeneration via CSF3R [#15, #16], and protects neurons through ERK and PI3K/Akt–GSK-3β survival pathways [#17, #18]. G-CSF is a pathogenic driver in the PLCG2 gain-of-function autoinflammatory disease APLAID, where anti-G-CSF antibody fully reverses disease, and it promotes tumor stem-cell maintenance and cancer cell invasion through STAT3 [#24, #14, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that distinct cytoplasmic tyrosines of the G-CSF receptor specify induction of different myeloid differentiation genes in cooperation with C/EBPα, resolving how a single receptor encodes program-specific outputs.\",\n      \"evidence\": \"Ba/F3 cells co-expressing C/EBPα-ER with tyrosine-to-alanine G-CSFR mutants, RT-PCR for MPO/NE/PU.1\",\n      \"pmids\": [\"11368439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor mechanism linking each tyrosine to a specific gene not defined\", \"Reconstitution in non-Ba/F3 primary progenitors not shown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined how leukemia-associated receptor truncations subvert signaling by removing the Tyr729 SOCS3 site, decoupling STAT5 inhibition from intact STAT3 inhibition to produce a hyperproliferative state.\",\n      \"evidence\": \"STAT3/STAT5 luciferase reporters, SOCS3 measurement in gcsfr-d715 mice, internalization assays, Tyr729 mutagenesis\",\n      \"pmids\": [\"15069015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link to leukemic transformation in patients not established\", \"Mechanism connecting internalization defect to SOCS3 loss not fully resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed STAT3 acts as a negative regulator of G-CSF signaling via SOCS3, with ERK becoming the dominant proliferative driver when STAT3 is absent, defining the feedback architecture of the pathway.\",\n      \"evidence\": \"Conditional Stat3-knockout hematopoietic cells, MEK1 inhibitor, ERK/SOCS3 Western blots, colony assays\",\n      \"pmids\": [\"15671148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative balance between STAT3, STAT5 and ERK in normal granulopoiesis not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated that G-CSF mobilizes hematopoietic cells through two routes—indirect suppression of osteoblast-derived CXCL12 and cell-autonomous CXCR4 downregulation on myeloid cells.\",\n      \"evidence\": \"G-CSFR mutant transgenic mice, histomorphometry and CXCL12 measurement; flow cytometry and SDF-1 migration assays on Gr1+ cells\",\n      \"pmids\": [\"16037394\", \"16537807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Indirect signal from G-CSFR-bearing cells to osteoblasts not identified\", \"Relative contribution of each route to net mobilization unquantified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended G-CSF function beyond hematopoiesis by showing direct receptor-mediated JAK/STAT3 anti-apoptotic protection of cardiomyocytes.\",\n      \"evidence\": \"Dominant-negative STAT3 transgenic cardiomyocytes in an in vivo myocardial infarction model\",\n      \"pmids\": [\"15723072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream Jak isoform usage in cardiomyocytes not specified\", \"Translation to human cardiac repair untested in this work\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified the membrane-proximal box1 PXP motif as essential for Jak1/Jak2/Tyk2 activation and STAT recruitment, and revealed that mature neutrophils use Jak-independent alternative pathways.\",\n      \"evidence\": \"Pro639Ala/Pro641Ala G-CSFR mutants in Ba/F3 and NFS-60 cells; kinase assays compared with primary neutrophils\",\n      \"pmids\": [\"9015216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the alternative Jak-independent pathway in neutrophils not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the architecture of ligand-receptor engagement, establishing a 2:2 stoichiometry analogous to IL-6 receptor site II/site III interactions.\",\n      \"evidence\": \"Crystal structure of ligand-binding domain with G-CSF plus mutagenesis and antibody mapping (review synthesis)\",\n      \"pmids\": [\"16720384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full-length receptor complex structure not determined\", \"Source is a compiled review rather than a single primary structure paper\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed G-CSF induces functional E-selectin ligands on myeloid cells by upregulating glycosyltransferases, linking the cytokine to adhesion under physiologic flow.\",\n      \"evidence\": \"Parallel-plate flow assay, intravital microscopy, enzymatic ablation, glycosyltransferase RT-PCR on human bone marrow cells\",\n      \"pmids\": [\"16980970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from G-CSFR to glycosyltransferase transcription not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Distinguished an ERK-dependent, JAK/STAT-independent neuroprotective mode of G-CSF in dopaminergic neurons.\",\n      \"evidence\": \"Primary mesencephalic cultures, 6-OHDA model, MEK/ERK inhibitor, Bad/Bcl-xL/caspase-3 Western blots\",\n      \"pmids\": [\"16839644\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic receptor knockout confirmation\", \"Single-lab pharmacological dissection\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Gab2 Tyr643 as the Jak2-phosphorylated docking site that recruits Shp2 to drive ERK activation and proliferation, providing the link between receptor Jaks and the Ras-ERK arm.\",\n      \"evidence\": \"JAK inhibitor, Jak2 antisense/dominant-negative, in vitro Jak2 kinase assay, Gab2 Tyr643 mutagenesis, proliferation assays\",\n      \"pmids\": [\"18644434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Gab2 is recruited to the receptor complex not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined an inflammatory transcriptional input to CSF3, showing SAA induces G-CSF via TLR2/NF-κB binding to the promoter CK-1 element.\",\n      \"evidence\": \"TLR2-knockout macrophages, anti-TLR2 blockade, NF-κB assay, promoter ChIP, in vivo SAA injection\",\n      \"pmids\": [\"18952897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological settings where SAA drives G-CSF in vivo not delineated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed Gfi1-driven RasGRP1 transcription as a selective requirement for G-CSF-induced ERK activation and granulocytic differentiation, and positioned G-CSF upstream of IL-21/IL-17 in Th17 differentiation.\",\n      \"evidence\": \"Gfi1-knockout mice with RasGRP1 rescue; transplantation model with IL-21/IL-17A knockout and cytokine staining\",\n      \"pmids\": [\"20203268\", \"20435882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting G-CSF to IL-21 induction in T cells not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed G-CSF activates Lyn through Gab2-recruited Shp2 dephosphorylating inhibitory Tyr507, and established a receptor-dependent role for G-CSF in skeletal muscle myoblast proliferation and regeneration.\",\n      \"evidence\": \"Co-IP, in vitro phosphatase assays, Shp2-deficient cells, Gab2 mutants; G-CSFR-knockout mice, neutralizing antibody, BrdU assay, muscle injury model\",\n      \"pmids\": [\"21636860\", \"21422169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Lyn activation for myeloid outcomes not fully defined\", \"Muscle-cell-intrinsic signaling pathway downstream of CSF3R not detailed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated G-CSF corrects neutrophil apoptosis and energy homeostasis in G6PC3 deficiency, linking the cytokine to metabolic and survival rescue in congenital neutropenia.\",\n      \"evidence\": \"G6pc3-knockout mice, in vivo G-CSF therapy, p-Akt/caspase-3 blots, glucose uptake and metabolite measurement\",\n      \"pmids\": [\"21292774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanistic link between CSF3R signaling and metabolite changes not established\", \"Single-lab in vivo study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established a PI3K/Akt–GSK-3β neuroprotective axis for G-CSF after neonatal hypoxia-ischemia that strictly requires CSF3R.\",\n      \"evidence\": \"Neonatal rat HI model, G-CSFR and GSK-3β siRNA, Wortmannin, TUNEL and Western blots\",\n      \"pmids\": [\"25448005\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic knockout; reliance on siRNA and pharmacology\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified autophagy as a specific downstream requirement for G-CSF-driven neutrophil and HSC mobilization, distinct from CXCR4-antagonist mobilization.\",\n      \"evidence\": \"Autophagy-deficient mice, G-CSF vs AMD3100 comparison, flow cytometry and autophagy flux assays in mouse and human cells\",\n      \"pmids\": [\"25788702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between CSF3R signaling and autophagy induction not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined PLCγ2 as upstream of JAK/STAT3 and PU.1 in G-CSF-induced granulopoiesis, and showed G-CSF supports satellite-cell-dependent muscle regeneration in dystrophy models.\",\n      \"evidence\": \"PLCγ2 shRNA and inhibitors with JAK1/STAT3/PU.1 blots and CFU assays; ex vivo fiber culture and in vivo treatment of mdx/DMD mice\",\n      \"pmids\": [\"24038146\", \"25865621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How PLCγ2 is positioned relative to box1/Jak activation not reconciled\", \"Satellite-cell-intrinsic signaling not dissected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a STAT3-mediated feed-forward loop by which G-CSF maintains cancer stem-cell subpopulations and upregulates its own receptor in neuroblastoma.\",\n      \"evidence\": \"CSC expansion assays, xenograft and murine tumor models, anti-G-CSF antibody, STAT3 inhibitor, G-CSFR transcriptional reporter\",\n      \"pmids\": [\"25908586\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of the feed-forward loop across other tumor types not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed LPS induces CSF3 transcription specifically through ERK2 (not ERK1), with C/EBPβ and NF-κB recruitment enabled by ERK2-driven chromatin remodeling.\",\n      \"evidence\": \"Isoform-specific ERK1/ERK2 shRNA, promoter-luciferase reporter, ChIP, DNase I accessibility assay\",\n      \"pmids\": [\"26114754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ERK2 selectively engages the promoter versus ERK1 not explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified IFNγ-induced SOCS3 as a negative regulator of G-CSF-driven neutrophil expansion, with G-CSF (not GM-CSF) specifically sustaining neutrophil survival.\",\n      \"evidence\": \"IFNγ-knockout mice, G-CSF/GM-CSF depletion antibodies, SOCS3 measurement, neutrophil apoptosis assays\",\n      \"pmids\": [\"29352287\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type source of IFNγ-SOCS3 crosstalk in vivo not fully resolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected tissue injury to emergency hematopoiesis through an IL-1/MyD88 pathway driving G-CSF production that expands HSC/MPP and myeloid-skewed progenitors, and showed G-CSF mediates osteoblast-suppressive bone loss during S. aureus infection.\",\n      \"evidence\": \"Polytrauma model with IL-1R/MyD88-knockout mice and G-CSF ELISA; S. aureus infection model with G-CSF ELISA, neutralizing antibody, microCT\",\n      \"pmids\": [\"30988118\", \"31175224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cellular source of G-CSF in each setting not fully resolved\", \"Single-lab studies\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed cancer-associated adipocyte-derived G-CSF promotes breast cancer invasion through STAT3-driven MMP2/MMP9 expression, extending the tumor-promoting STAT3 axis to the stromal microenvironment.\",\n      \"evidence\": \"Primary cancer-associated adipocytes, recombinant G-CSF, neutralizing antibody, Stat3 siRNA/inhibitor, migration/invasion assays, transcriptomics\",\n      \"pmids\": [\"32242230\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo contribution of adipocyte-derived G-CSF to metastasis not tested\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established G-CSF as the key pathogenic driver of APLAID autoinflammation, with anti-G-CSF antibody fully reversing disease and bone marrow transplant identifying a non-hematopoietic G-CSF source.\",\n      \"evidence\": \"APLAID PLCG2 knock-in mice, anti-G-CSF antibody, bone marrow transplantation, cytokine profiling, flow cytometry\",\n      \"pmids\": [\"36997670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the non-hematopoietic G-CSF-producing cell not defined\", \"Translation to human APLAID untested in this work\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CSF3R endosomal trafficking, ubiquitination and redox-controlled phosphatase activity quantitatively tune signal amplitude and the switch from proliferation to differentiation remains unresolved at the molecular level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Mechanistic detail rests on a review without new primary experiments [#26]\", \"Specific ubiquitin ligases and endosomal phosphatases not identified\", \"Link between receptor routing and downstream STAT/ERK balance not directly demonstrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [11, 12]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 11, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13, 21, 22, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 22, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [13, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [15, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CSF3R\", \"JAK2\", \"STAT3\", \"GAB2\", \"PTPN11\", \"LYN\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}